De Sousa Sena, R., Ahmed, S., Tan, W. C., Li, P. Z., Labonté, L., Aaron, S. D., Benedetti, A., Chapman, K. R., Walker, B., Fitzgerald, J. M., Hernandez, P., Maltais, F., Marciniuk, D. D., O'Donnell, D. E., Sin, D. D., & Bourbeau, J. (2017). Work productivity loss in mild to moderate COPD: Lessons learned from the CanCOLD study. European Respiratory Journal, 50(3), Article 01154. https://doi.org/10.1183/13993003.01154-2017
Work productivity loss in mild to moderate COPD: Lessons learned from the CanCOLD study. / De Sousa Sena, Riany; Ahmed, Sara; Tan, Wan C. et al.
In:
European Respiratory Journal, Vol. 50, No. 3, 01154, 01.09.2017.
Research output: Contribution to journal › Letter › peer-review
De Sousa Sena, R, Ahmed, S, Tan, WC, Li, PZ, Labonté, L, Aaron, SD, Benedetti, A, Chapman, KR, Walker, B, Fitzgerald, JM, Hernandez, P, Maltais, F, Marciniuk, DD, O'Donnell, DE, Sin, DD & Bourbeau, J 2017, 'Work productivity loss in mild to moderate COPD: Lessons learned from the CanCOLD study', European Respiratory Journal, vol. 50, no. 3, 01154. https://doi.org/10.1183/13993003.01154-2017
De Sousa Sena R, Ahmed S, Tan WC, Li PZ, Labonté L, Aaron SD et al. Work productivity loss in mild to moderate COPD: Lessons learned from the CanCOLD study. European Respiratory Journal. 2017 Sept 1;50(3):01154. doi: 10.1183/13993003.01154-2017
De Sousa Sena, Riany ; Ahmed, Sara ; Tan, Wan C. et al. / Work productivity loss in mild to moderate COPD : Lessons learned from the CanCOLD study. In: European Respiratory Journal. 2017 ; Vol. 50, No. 3.
@article{4c2dbc61aa164a8796f952a75e0d519c,
title = "Work productivity loss in mild to moderate COPD: Lessons learned from the CanCOLD study",
author = "{De Sousa Sena}, Riany and Sara Ahmed and Tan, {Wan C.} and Li, {Pei Z.} and Laura Labont{\'e} and Aaron, {Shawn D.} and Andrea Benedetti and Chapman, {Kenneth R.} and B. Walker and Fitzgerald, {J. Mark} and Paul Hernandez and Fran{\c c}ois Maltais and Marciniuk, {Darcy D.} and O'Donnell, {Denis E.} and Sin, {Don D.} and Jean Bourbeau",
note = "Funding Information: Support statement: The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network (CRRN); industry partners: Astra Zeneca Canada Ltd; Boehringer Ingelheim Canada Ltd; GlaxoSmithKline Canada Ltd; and Novartis. Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners are the CIHR (CIHR/Rx&D Collaborative Research Program Operating Grants 93326); the Respiratory Health Network of the Fonds de la recherche en sant{\'e} du Qu{\'e}bec (FRSQ); industry partners: Almirall; Merck Nycomed; Pfizer Canada Ltd; and Theratechnologies. The funders had no role in study design, data collection and analysis, or preparation of the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.",
year = "2017",
month = sep,
day = "1",
doi = "10.1183/13993003.01154-2017",
language = "English",
volume = "50",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",
}
TY - JOUR
T1 - Work productivity loss in mild to moderate COPD
T2 - Lessons learned from the CanCOLD study
AU - De Sousa Sena, Riany
AU - Ahmed, Sara
AU - Tan, Wan C.
AU - Li, Pei Z.
AU - Labonté, Laura
AU - Aaron, Shawn D.
AU - Benedetti, Andrea
AU - Chapman, Kenneth R.
AU - Walker, B.
AU - Fitzgerald, J. Mark
AU - Hernandez, Paul
AU - Maltais, François
AU - Marciniuk, Darcy D.
AU - O'Donnell, Denis E.
AU - Sin, Don D.
AU - Bourbeau, Jean
N1 - Funding Information:
Support statement: The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network (CRRN); industry partners: Astra Zeneca Canada Ltd; Boehringer Ingelheim Canada Ltd; GlaxoSmithKline Canada Ltd; and Novartis. Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners are the CIHR (CIHR/Rx&D Collaborative Research Program Operating Grants 93326); the Respiratory Health Network of the Fonds de la recherche en santé du Québec (FRSQ); industry partners: Almirall; Merck Nycomed; Pfizer Canada Ltd; and Theratechnologies. The funders had no role in study design, data collection and analysis, or preparation of the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.
PY - 2017/9/1
Y1 - 2017/9/1
UR - http://www.scopus.com/inward/record.url?scp=85030032244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030032244&partnerID=8YFLogxK
U2 - 10.1183/13993003.01154-2017
DO - 10.1183/13993003.01154-2017
M3 - Letter
C2 - 28899939
AN - SCOPUS:85030032244
SN - 0903-1936
VL - 50
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 3
M1 - 01154
ER -